Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
VitiligoChildProgressive Disease
Interventions
DRUG

Tacrolimus

Participants receive oral tacrolimus capsules at a dosage of 0.1 ± 0.05 mg/kg per day, divided into two administrations. The treatment duration is 24 weeks. Blood drug concentration is monitored to maintain trough levels between 7-15 ng/mL. Safety assessments include regular blood tests (hematology, liver/kidney function, blood glucose) and adverse event tracking.

DRUG

Dexamethasone

Participants receive oral dexamethasone tablets at a dosage of 0.05 ± 0.025 mg/kg per day, administered as a single dose on weekends (Saturday and Sunday). The treatment duration is 24 weeks. Safety evaluations include monitoring of blood parameters (hematology, liver/kidney function, blood glucose), weight, and adrenal function (cortisol, ACTH levels).

Trial Locations (1)

710032

RECRUITING

Xijing Hospital, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER